DAFNA Capital Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

DAFNA Capital Management’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-50,000	Closed	-$119K	–	83
2023 Q4	$119K	Sell	50,000 -55,179	-52%	-$97.7K	0.03%	75
2023 Q3	$147K	Buy	105,179 +25,000	+31%	+$60K	0.05%	73
2023 Q2	$243K	Sell	80,179 -829	-1%	-$3.2K	0.07%	69
2023 Q1	$506K	Buy	81,008 +10,000	+14%	+$60.9K	0.15%	60
2022 Q4	$433K	Sell	71,008 -7,066	-9%	-$57.5K	0.12%	64
2022 Q3	$933K	Sell	78,074 -146,377	-65%	-$1.92M	0.25%	61
2022 Q2	$2.83M	Buy	224,451 +76,300	+52%	+$710K	0.77%	36
2022 Q1	$1.67M	Buy	148,151 +41,698	+39%	+$459K	0.43%	56
2021 Q4	$1.89M	Hold	106,453	–	–	0.47%	46
2021 Q3	$2.45M	Buy	106,453 +52,038	+96%	+$1.13M	0.65%	42
2021 Q2	$1.27M	Buy	54,415 +1,500	+3%	+$38.2K	0.27%	68
2021 Q1	$1.65M	Sell	52,915 -15,206	-22%	-$530K	0.39%	56
2020 Q4	$2.71M	Buy	+68,121	New	+$2.73M	0.81%	30

Other funds holding KNTE

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DAFNA Capital Management's KNTE Position: Q1 2024 in Review

DAFNA Capital Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2024, closing a stake of 50,000 shares — an estimated $119K sold.

DAFNA Capital Management first reported a position in KNTE in Q4 2020 and held it in 13 quarters. The position peaked at $2.83M in Q2 2022. 56 funds tracked by Wall St. Rank hold KNTE as of Q1 2024.

DAFNA Capital Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
DAFNA Capital Management sold 50,000 Kinnate Biopharma Inc. Common Stock shares in Q1 2024, an estimated $119K.
DAFNA Capital Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 13 quarters.
DAFNA Capital Management's Kinnate Biopharma Inc. Common Stock position peaked at $2.83M in Q2 2022.
56 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2024.

Based on DAFNA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.